|
The Carroll Center for the Blind, in partnership with Alkeus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for serious retinal diseases, invites you to a free webinar designed to educate individuals on the advancing research they have done for Stargardt s Disease. This special webinar offers a unique opportunity to learn about the latest advancements in Stargardt disease research, hear from an expert developing potential new treatments, and engage directly with the Alkeus team in a welcoming and accessible environment.Speaker: Dr. Carlos Quezada-Ruiz, Chief Medical Officer at AlkeusWhether you are personally affected, supporting a loved one, or simply interested in the future of retinal research, we invite you to join this important conversation. This is a valuable opportunity to hear firsthand what participation in a clinical trial might be like and how research studies like NORTHSTAR are shaping the future of care, directly from Alkeus Chief Medical Officer. About the SpeakerDr. Carlos Quezada-Ruiz is a retina specialist with over 15 years of clinical experience and leadership in drug development, currently serving as Chief Medical Officer at Alkeus and previously at Genentech/Roche and 4D Molecular Therapeutics. He has contributed to breakthrough therapies, including Vabysmo, SUSVIMO, and gene therapies, and has led multiple regulatory filings resulting in approvals in the retina field. He has authored more than 40 scientific publications and remains active in research, teaching, and global collaboration. Dr. Quezada-Ruiz has served on the scientific committee of the Mexican Retina Society and the editorial board of the Mexican Journal of Ophthalmology, and is a Fellow of the American Society of Retina Specialists (ASRS) and a member of AAO, ARVO, EURETINA, PAAO, AMR, SMO, and ACOREV. |
